Active transport of rhodamine 123 by the human multidrug transporter P‐glycoprotein involves two independent outer gates

Abstract

Human P-glycoprotein (P-gp) is a multispecific drug-efflux transporter, which plays an important role in drug resistance and drug disposition. Recent cryo-electron microscopy structures confirmed its rotationally symmetric architecture, which allows dual interaction with ATP and substrates. We here report the existence of two distinct, symmetry-related outer gates. Experiments were aided by availability of the X-ray structure of a homodimeric eukaryotic homolog of P-gp from red alga (CmABCB1), which defined the role of an apical tyrosine residue (Y358) in outer gate formation.We mutated analogous tyrosine residues in each half of the human full-length transporter (Y310, Y953) to alanine. These mutants were introduced in engineered transporters which bind rhodamine 123 in one of two symmetry-related binding modes only. Outer gate dysfunction was detected by a loss of active transport characteristics, while these mutants retained the ability for outward downhill transport. Our data demonstrate that symmetric tyrosine residues Y310 and Y953 are involved in formation of two distinct symmetry-related outer gates, which operate contingent on the rhodamine 123 binding mode. Hence, the rotationally symmetric architecture of P-gp, which determines duality in ATP binding and rhodamine 123 interaction, also forms the basis for the existence of two independently operating outer gates. K E Y W O R D S ABC transporter, ABCB1, functional biology, multidrug transporter, outer gates, P-glycoprotein S U PP O RTI N G I N FO R M ATI O N Additional supporting information may be found online in the Supporting Information section. How to cite this article: Nasim F, Schmid D, Szakács G, et al. Active transport of rhodamine 123 by the human multidrug transporter P-glycoprotein involves two independent outer gates. Pharmacol Res Perspect. 2020;00:e00572. https://doi.

The role of the degenerate nucleotide binding site in type I ABC exporters

“…The chloride channel ABCC7 seems to have a noncentral narrow gate located between TMH6 and TMH1 [68,149]. Mutational and biochemical data suggest that two small gates are most likely present in ABCB1, because introducing positively charged arginine residues in symmetry-related position of TMH2 and 8, combined with nearby mutations, selectively affected the transport of charged substrates [150][151][152], thus implying two symmetry-related gates. Structures of human ABCB1 [54] show a bound taxol that is large enough to fill the entire substrate-binding cavity.…”

“…In contrast, ATP‐driven, primary active transporters show unidirectional transport. Two types of mutations were reported, which converted unidirectional ABC transporters to a bidirectional ATP‐gated facilitator: (a) mutations in the putative substrate‐binding/translocation path of the TMD of ABCB1 resulted in a transporter variant that shows concentration gradient dependent substrate translocation [152], and (b) mutations of the D‐loop of ABCB2/B3 [94] and ABCB9 [154] converted these transporters to ATP‐gated substrate translocation facilitator.…”

Decrease of ABCB1 protein expression and increase of G1 phase arrest induced by oleanolic acid in human multidrug‑resistant cancer cells

“…Since Rho 123 is the substrate of ABCB1, its fluorescence intensity can be used as an indicator of the relative levels of ABCB1 ( 15 , 21 ). A total of 2x10 5 cells from the 4 cell lines per well at the logarithmic growth phase were seeded into a six-well plate.…”

Chemical molecular‐based approach to overcome multidrug resistance in cancer by targeting P‐glycoprotein (P‐gp)

“…Finally, except for 17, the P-gp selective profile for other compounds in this class is still unknown. , and they inhibited P-gp-mediated efflux of DOX and rhodamine 123 (Rh123, a P-gp substrate 93 ), respectively, indicating that the MDR-reversal efficacy was due to the potent inhibition of P-gp.…”

“…This compound significantly reversed DOX‐resistance in P‐gp‐overexpressing K562/DOX cells and had high RF values (RF = 33 at a concentration of 1 μM; RF = 58 at a concentration of 3 μM). Further mechanistic studies indicated that Compounds 18 and 19 increased the intracellular accumulation of the P‐gp substrate (DOX for 18 and pirarubicin for 19 ), and they inhibited P‐gp‐mediated efflux of DOX and rhodamine 123 (Rh123, a P‐gp substrate 93 ), respectively, indicating that the MDR‐reversal efficacy was due to the potent inhibition of P‐gp. Moreover, 18 was shown to be a selective P‐gp inhibitor as it has no effect on multidrug resistance protein 1 (MRP1/ ABCC1 ) 94 or breast cancer resistance protein (BCRP/ ABCG2 ), 95 two MDR‐related ABC transporters present in certain cancer cells.…”